Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical : Proxy Forms

06/22/2021 | 05:17am EDT

上 海 復 星 醫 藥( 集 團 )股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

FORM OF PROXY FOR HOLDERS OF H SHARES

FOR THE 2021 SECOND EXTRAORDINARY GENERAL MEETING

TO BE HELD ON WEDNESDAY, 14 JULY 2021

I/We(Note 1)

of

being the holder(s) of overseas listed

foreign share(s) (H share(s))(Note 2) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company''), hereby appoint the chairman of the meeting or

of

as my/our proxy(Note 3) to vote and act for me/us at the 2021 second extraordinary general meeting (the ''EGM'') of the Company to be held on Wednesday, 14 July 2021 at 1:30 p.m. at Shanghai Film Art Center, No. 160 Xinhua Road, Shanghai, the PRC to vote for me/us as indicated below. Unless otherwise stated, capitalized terms used herein shall have the same meanings as that defined in the circular of the Company dated 23 June 2021 (the ''Circular'').

Please tick or insert the number of H Shares in the appropriate boxes to indicate how you wish your vote(s) to be cast on a poll.(Note 4)

SPECIAL RESOLUTION

For(Note 4)

Against(Note 4) Abstain(Note 4)

1 To consider and approve the resolution on the Report on the Use of Proceeds Previously Raised

Signed this

day of

2021

Signature(s)(Note 5) :

Notes:

  1. IMPORTANT: You should first review the Circular carefully before filling in this proxy form.
  2. Full name(s) and address(es) (as shown in the register of members for H Shares) to be inserted in BLOCK CAPITALS.
  3. Please insert the number of H Shares registered in your name(s). If no number is inserted, this form of proxy will be deemed to relate to all the H Shares registered in your name(s).
  4. The health of shareholders, staff and stakeholders is of paramount importance to the Company. If any proxy other than the chairman of the meeting is preferred, please strike out the words ''the chairman of the meeting or'' and insert the name and address of the proxy desired in the space provided. An H Shareholder entitled to attend and vote at the EGM is entitled to appoint one or more proxies to attend and vote on his behalf. A proxy need not be a member of the Company. If more than one proxy is so appointed, the appointment shall specify the number of H Shares in respect of which each such proxy is so appointed. Any alteration made to this form of proxy must be initialled by the person who signs it.
  5. Important: if you wish to vote for any resolution, tick in the box marked ''For''. If you wish to vote against any resolution, tick in the box marked ''Against''. If you wish to abstain from voting on any resolution, tick in the box marked ''Abstain''. Any abstain vote at the EGM shall be disregarded as voting rights for the purpose of calculating the result of that resolution, but will be counted in the total number of voting shares. If you wish to vote only part of the H Shares in respect of which the proxy is so appointed, please state the exact number of H Shares in lieu of a tick in the relevant box. A tick in the relevant box indicates that the votes attached to all the H Shares to which this form relates will be cast accordingly. Unless you have indicated otherwise in this form, your proxy will also be entitled to vote at his discretion on any resolution properly put to the EGM other than those referred to in the notice convening the EGM.
  6. This proxy form must be signed by you or your attorney duly authorised in writing or, in the case of a corporation, must either be executed under its common seal or under the hand of an officer or attorney duly authorised.
  7. In case of joint holders, the vote of the joint holder whose name stands first in the register of members for H Shares and who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of other joint holder(s), and for this purpose seniority shall be determined by the order in which the names stand in the register of members for H Shares in respect of such joint holding.
  8. In order to be valid, this form of proxy together with the power of attorney or other authority (if any) under which it is signed or a certified copy thereof, must be deposited at the Company's Hong Kong share registrar for H Shares, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong no later than 24 hours before the holding of the EGM or any adjournment thereof.
  9. Completion and delivery of this form of proxy will not preclude you from attending and voting at the EGM if you so wish.
  10. The description of the resolution is by way of summary only. The full text appears in the notice convening the EGM, which is set out in the Circular.
  • for identification purposes only

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 22 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 June 2021 09:16:04 UTC.


ę Publicnow 2021
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
02:21aSHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Joins Buyer Consortium for $1.6 Bil..
MT
08/04SHANGHAI FOSUN PHARMACEUTICAL : VOLUNTARY ANNOUNCEMENT – PARTICIPATION IN ..
PU
08/03SHANGHAI FOSUN PHARMACEUTICAL : Monthly return of equity issuer on movements in ..
PU
08/02SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Wins Regulatory Nod for $770 Millio..
MT
08/02SHANGHAI FOSUN PHARMACEUTICAL : Announcement on the approval from csrc for the p..
PU
07/28SHANGHAI FOSUN PHARMACEUTICAL : An announcement has just been published by the i..
PU
07/19Sisram Medical Seeks $80 Million in Private Placement; Shares Fall 6%
MT
07/19SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement entering into the placing..
PU
07/19SHANGHAI FOSUN PHARMACEUTICAL (GROUP : Ex-dividend day for final dividend
FA
07/14SINOVAC BIOTECH : Fosun-BioNTech COVID-19 vaccine completes China regulator revi..
RE
More news
Financials
Sales 2021 40 184 M 6 216 M 6 216 M
Net income 2021 4 372 M 676 M 676 M
Net Debt 2021 15 917 M 2 462 M 2 462 M
P/E ratio 2021 51,4x
Yield 2021 0,59%
Capitalization 211 B 32 647 M 32 656 M
EV / Sales 2021 5,65x
EV / Sales 2022 4,99x
Nbr of Employees 32 258
Free-Float 58,8%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | 600196 | CNE000000X38 | MarketScreener
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 87,40 CNY
Average target price 57,08 CNY
Spread / Average Target -34,7%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman
Sector and Competitors